Genetic Vaccination against Experimental Infection with Myotropic Parasite Strains of Trypanosoma cruzi
Figure 5
Impact of therapeutic vaccination in the immunity of resistant mice. (a) F1 (CB10XBALB/c) female mice were challenged s.c. with 1,000 trypomastigotes of the indicated parasite strain. Thirty days later, G2 mice received a mixture of control plasmid pcDNA3 and of pIL-12 (300 μg), and G3 mice were immunized with a mixture of pIL-12, pIgSPCl9, and p154/13 (300 μg). Twenty days later, these mice received, in these same spots, 100 μL of a viral suspension containing a total of 2 × 108 pfu of rec. adenovirus. For boosting, G2 mice received control adenovirus Adβgal, and G3 mice were immunized with a mixture of rec. adenovirus AdASP-2 and Ad-TS. (b) Mean parasitemia ± SD of each mouse group () challenged with parasites of the Brazil strain. (c) Mean parasitemia ± SD of each mouse group () challenged with parasites of the Colombian strain.
